Preclinical News and Research

RSS

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen announced today the initiation of the first clinical trial of the Company's proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

Milestone completes $13 million round of equity financing

Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing.

13 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Eli Lilly, Synthes collaborate to develop osteoinductive products

Synthes, Inc. and Eli Lilly and Company today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.

10 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa).

9 Jun 2011

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

8 Jun 2011

Preclinical News and Research

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Adaptimmune melanoma trial opening

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

Milestone completes $13 million round of equity financing

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Eli Lilly, Synthes collaborate to develop osteoinductive products

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics